GHS-R1a is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
== Genetics == LADA appears to share genetic risk factors with both T1D and T2D, including susceptibility loci related to HLA-associated immune function as well as loci associated with insulin resistance, but is genetically distinct from both. Within the LADA patient group, a phenotypic heterogeneity has been observed with varying degrees of insulin resistance and autoimmunity. As a result, LADA is considered a heterogeneous and complex genetic disorder.
=== Ben Cousins === Ben Cousins played for the West Coast Eagles and Richmond Football Club in his 12 years of playing AFL. On 16 October 2007, Cousins was arrested in Northbridge, Perth, after police had pulled his vehicle over "due to the manner of his driving". Police searched his car and found quantities of prohibited drugs. Cousins was then sacked by West Coast after serious breaches of his contract with them. In 2009, Cousins joined Richmond to continue his AFL career, but on 12 April Cousins and three other Richmond players were suspended by the club after a drunken altercation in a Sydney hotel. Although Cousins was not intoxicated it was ruled that he had not acted responsibly leading to his suspension for 1 week. A few months later in July, Cousins was admitted to hospital after a severe reaction to the prescribed sleeping pills he had taken. This incident led to the debate of whether legal stimulants (such as caffeine) and legal sedatives (such as sleeping pills) could be used by athletes. The Premier of Victoria, John Brumby, disapproved of their use within sporting events.
Circulating levels of 0.6 ng/mL with 2% solution and 1.6 ng/mL with 5% solution occur with topical minoxidil. However, levels vary between individuals, with a range of undetectable to 7.5 ng/mL with 3% solution in 12 individuals in one study. Significant cardiological and hemodynamic effects are said to occur with minoxidil when serum minoxidil levels exceed 20 ng/mL.
Sources: en.wikipedia.org
== Uses == Gochujang is used in various dishes such as bibimbap and tteokbokki, and in salads, stews, soups, and marinated meat dishes. Gochujang may make dishes spicier (depending on the capsaicin in the base chili), but also can make them sweeter and smokier.
== Modern therapeutic research == Tetrodotoxin has been investigated as a possible treatment for cancer-associated pain. Early clinical trials demonstrate significant pain relief in some patients. It has also been studied in relation to migraine headaches. Mutations in one particular TTX-sensitive Na+ channel are associated with some migraine headaches, although it is unclear as to whether this has any therapeutic relevance for most people with migraine. Tetrodotoxin has been used clinically to relieve negative affects associated with heroin withdrawal.
=== Cosmetic uses === Tranexamic acid can be used in skincare products as a cosmetic active to reduce the appearance of inflammation and hyperpigmentation. Tranexamic acid is a zwitterion amino acid, and has a low permeability coefficient in the stratum corneum. Tranexamic acid can be combined with penetration enhancers and microneedling to overcome this limitation. Cosmetic uses may also employ lipophilic derivatives of tranexamic acid (ester prodrugs like Cetyl tranexamate mesylate) that are not zwitterionic and thus have improved skin permeability.
==== Mayhew's leaked letter ==== By now the political row was being discussed in the media, partly because of the lack of other news in December. Cuckney wrote to Thatcher, at her behest, asking for reassurance that the Sikorsky deal would not damage Westland's business prospects in Europe. Heseltine was not satisfied with Thatcher's draft reply when he saw it and consulted Sir Patrick Mayhew (Solicitor-General and acting attorney-general as Sir Michael Havers was ill) on the grounds that the government might be legally liable for any incorrect advice. Heseltine supplied extra material about the risk of losing European business, which Thatcher did not include in her reply to Cuckney. Heseltine then wrote to David Horne of Lloyds Merchant Bank, who was advising the European consortium (in reply to planted questions from Horne which had been dictated to him over the phone by one of Heseltine's staff), giving him the advice which Thatcher had declined to include in her letter to Cuckney (that the Sikorsky deal would be "incompatible with participation" in European helicopter projects). Heseltine's letter was also leaked to the press. This was a blatant challenge to Thatcher's authority as Heseltine had not consulted Downing Street, the Department of Trade and Industry or Mayhew before writing to Horne. Thatcher discussed sacking Heseltine with close colleagues over Christmas; but, as she later admitted in her memoir, refrained from doing so as he was too popular and important as a political figure.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
Typical guidance is -20 °C in a sealed container with desiccant and protection from light. The powder tolerates handling better than a solution, but repeated warming and cooling is still avoided.